Does Biological Sex Influence Insulin Sensitivity and Muscle Metabolism Following High-intensity Interval Exercise?

August 18, 2025 updated by: Jenna Gillen, University of Toronto
High-intensity interval exercise (HIIE) is a type of exercise that involves alternating periods of intense exercise with periods of rest. HIIE has been shown to improve many aspects of cardiovascular and metabolic health in a time-efficient manner (e.g., only 20 minutes per exercise session). An important health benefit of exercise is improved blood sugar control, which can help reduce the risk of metabolic diseases like type 2 diabetes. A single session of HIIE has been shown to improve blood sugar in males, but it is unknown if females achieve the same health benefit. It is also not fully understood how exercise improves blood sugar in males and females. Therefore, the purpose of this project is 1) to determine if a single session of HIIE improves blood sugar control in males and females, and 2) to evaluate if changes in skeletal muscle can explain the beneficial effects of HIIE on blood sugar.

Study Overview

Detailed Description

The primary purpose of this study is to determine if biological sex influences the effects of high-intensity interval exercise (HIIE) on insulin sensitivity and muscle mechanisms. The investigators will measure insulin sensitivity and muscle outcomes of participants on two separate occasions: 1) Following 30 minutes of sitting in the lab; and 2) Following a single session of HIIE on a stationary bike. Insulin sensitivity will be measured by taking blood samples after participants consume a sugary drink. Muscle outcomes will be measured by taking a small amount of muscle from the vastus lateralis (thigh) muscle. Groups of male and female participants will be recruited and tested using best practice guidelines for sex-based comparisons of exercise responses.

The study will advance knowledge regarding the potential for biological sex to influence the metabolic responses high-intensity exercise.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5S2C9
        • Goldring Centre for High Performance Sport

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18-35 yrs
  • VO2peak considered recreationally active as defined as 'fair' or 'good' (males: 41.6- 50.5ml/kg/min; females: 35-41.9 ml/kg/min) based on Canadian Society for Exercise Physiology (CSEP) normative fitness values.
  • BMI between 18-27 kg/m2
  • 1-3 structured exercise sessions/week, and not training for any specific sport
  • Weight stable (within ± 2kg for at least 6 months)
  • Eumenorrheic (female only), defined as menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year)
  • Non-smoker

Exclusion Criteria:

  • Diagnosed with cardiovascular or metabolic disease, hyper- or hypogonadism, and/or polycystic ovarian syndrome (PCOS)
  • The use of medication for managing blood glucose or lipid metabolism
  • Current use of oral contraceptives or use within the last 3 months
  • Irregular menstrual cycles (<21 days or >35 days)
  • Pregnant, lactating, or menopausal
  • Recreational smoking of any kind
  • Inability to perform the study exercise protocols or follow the pre-trial dietary or physical activity controls
  • Taking medications affecting substrate metabolism (corticosteroids or nSAIDs)
  • Actively engaging in a low-carbohydrate diet (e.g., ketogenic, Atkins)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Females
Female participant group
Sitting for 30 minutes
Performing a single session of high-intensity interval exercise on a cycle ergometer
Experimental: Males
Male participant group
Sitting for 30 minutes
Performing a single session of high-intensity interval exercise on a cycle ergometer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insulin area under the curve
Time Frame: 3 hours
Insulin area under the curve measured during glucose tolerance test
3 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glucose area under the curve
Time Frame: 3 hours
Glucose area under the curve measured during glucose tolerance test
3 hours
Mean insulin concentration
Time Frame: 3 hours
Mean insulin concentration measured during glucose tolerance test
3 hours
Mean glucose concentration
Time Frame: 3 hours
Mean glucose concentration measured during glucose tolerance test
3 hours
Peak insulin concentration
Time Frame: 3 hours
Peak insulin concentration measured during the glucose tolerance test
3 hours
Peak glucose concentration
Time Frame: 3 hours
Peak insulin concentration measured during the glucose tolerance test
3 hours
Insulin:glucose ratio
Time Frame: 3 hours
Insulin to glucose ration measured during the glucose tolerance test
3 hours
Postprandial glucose oxidation
Time Frame: 3 hours
Postprandial glucose oxidation measured with a metabolic tracer
3 hours
Skeletal muscle glycogen content
Time Frame: immediately before and after exercise
Muscle glycogen use during exercise
immediately before and after exercise
Skeletal muscle contractile signaling protein content
Time Frame: immediately before and after exercise
Measured via western blotting
immediately before and after exercise
Skeletal muscle insulin signaling
Time Frame: 1hr into glucose tolerance test
Measured via western blotting
1hr into glucose tolerance test
Mitochondrial gene expression
Time Frame: Change from pre-exercise to 3hr post-exercise
Measured via Reverse transcription polymerase chain reaction
Change from pre-exercise to 3hr post-exercise
Muscle protein synthesis rates
Time Frame: 3hr post-exercise
Muscle protein synthesis rates assessed by incorporation of oral stable isotope tracer following exercise
3hr post-exercise
Local muscle oxygenation
Time Frame: During exercise
Muscle oxygenation (vastus lateralis) assessed with near-infrared spectroscopy (NIRS)
During exercise
Local muscle oxygenation
Time Frame: Pre-exercise, immediately post-exercise and 2 hrs post-exercise
Muscle oxygenation (vastus lateralis) assessed with NIRS during and following thigh cuff inflation
Pre-exercise, immediately post-exercise and 2 hrs post-exercise

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Stephanie Estafanos, MSc, University of Toronto

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2023

Primary Completion (Actual)

June 26, 2025

Study Completion (Actual)

June 26, 2025

Study Registration Dates

First Submitted

September 27, 2023

First Submitted That Met QC Criteria

October 4, 2023

First Posted (Actual)

October 10, 2023

Study Record Updates

Last Update Posted (Actual)

August 19, 2025

Last Update Submitted That Met QC Criteria

August 18, 2025

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 44435

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise

Clinical Trials on Seated Rest (Non-exercise control)

Subscribe